Patents Issued in January 14, 2003
-
Patent number: 6506765Abstract: Apomorphine derivative compounds; pharmaceutically active compositions of apomorphine derivative compounds; and the use of apomorphine derivative compounds in methods for treating sexual dysfunction or for enhancing apomorphine effectiveness for patients treated with apomorphine are disclosed. The apomorphine derivatives may be esters, ethers, amides, mixed anhydrides, hemiacetals, glucuronates, sulfates or phosphonates. A preferred apomorphine derivative is norapomorphine.Type: GrantFiled: March 29, 2001Date of Patent: January 14, 2003Assignee: TAP Pharmaceutical Products, Inc.Inventors: Pramod K. Gupta, Deborah Milkowski, Debra Sutkowski-Markmann
-
Patent number: 6506766Abstract: Compounds having Formula I are useful for partially or fully antagonizing, repressing, agonizing, or modulating the glucocorticoid receptor and treating immune, autoimmune and inflammatory diseases in a mammal. Also disclosed are pharmaceutical compositions comprising compounds of Formula I and methods of inhibiting immune or autoimmune diseases in a mammal.Type: GrantFiled: July 5, 2000Date of Patent: January 14, 2003Assignees: Abbott Laboratories, Ligand Pharmaceuticals IncorporatedInventors: Michael J. Coghlan, James P. Edwards, Steven W. Elmore, Todd K. Jones, Michael E. Kort, Philip R. Kym, Jimmie L. Moore, John K. Pratt, Alan X. Wang
-
Patent number: 6506767Abstract: Crystalline polymorphs of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cycloheptic[1,2-b]pyridine represented by the formula pharmaceutical compositions containing such polymorphs, and methods of using such polymorphs to treat allergic reactions in mammals such as man are disclosed.Type: GrantFiled: July 1, 1998Date of Patent: January 14, 2003Assignee: Schering CorporationInventors: Doris P. Schumacher, Junning Lee, Lawrence R. Rogers, Charles G. Eckhart, Naneshwar S. Sawant, Michael B. Mitchell
-
Patent number: 6506768Abstract: The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein R1 is hydrogen, optionally substituted C1-6alkyl, aryl; R2 is each independently a halogen, hydroxy, C1-6alkyl, C1-6alkyloxy or nitro; n is 0, 1, 2 or 3; Alk is C1-6alkanediyl; D is an optionally substituted saturated or unsaturated nitrogen containing heterocycle; and aryl is optionally substituted phenyl; having a great therapeutic breadth. It further relates to their use as a medicine, their preparation as well as compositions containing them.Type: GrantFiled: August 15, 2001Date of Patent: January 14, 2003Assignee: Janssen Pharmaceutica N.V.Inventors: Ludo Edmond Josephine Kennis, Josephus Carolus Mertens
-
Patent number: 6506769Abstract: Disclosed are novel compounds of formula (I): wherein Ar1, Ra, R4, R5, X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases associated with such kinases, for example, diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are processes for preparing these compounds, novel intermediates useful in these processes and compositions comprising compounds of the formula (I).Type: GrantFiled: August 2, 2001Date of Patent: January 14, 2003Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Roger John Snow, Mario Cardozo, Daniel Goldberg, Abdelhakim Hammach, Tina Morwick, Neil Moss, Usha R. Patel, Anthony S. Prokopowicz, III, Hidenori Takahashi, Matt Aaron Tschantz, Xiao-Jun Wang
-
Patent number: 6506770Abstract: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.Type: GrantFiled: July 8, 1998Date of Patent: January 14, 2003Assignee: AnorMED, Inc.Inventors: Gary James Bridger, Eva Maria Boehringer, Zhongren Wang, Dominique Schols, Renato Tony Skerlj, David Earl Bogucki
-
Patent number: 6506771Abstract: The present application describes heteroaryl-phenyl heterobicycles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.Type: GrantFiled: June 22, 2001Date of Patent: January 14, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Donald J. P. Pinto, Mimi L. Quan, Francis J. Woerner, Renhua Li
-
Patent number: 6506772Abstract: Substituted [1,2,4]triazolo[1,5a]pyridine derivatives and pharmaceutically active salts thereof with activity as adenosine receptor ligands are disclosed. These compounds are useful for treatment of diseases responsive to modulation of the adenosine receptor.Type: GrantFiled: November 30, 2001Date of Patent: January 14, 2003Assignee: Hoffmann-La Roche Inc.Inventors: Bernd Brodbeck, Matthias Heinrich Nettekoven
-
Patent number: 6506773Abstract: Pharmacologically active compounds are provided as well as pharmaceutical compositions and methods for treating cancer; inflammation; an autoimmune, infectious or ocular disease; or age-related macular degeneration in a mammal.Type: GrantFiled: May 15, 2001Date of Patent: January 14, 2003Assignee: Darwin Discovery Ltd.Inventors: Duncan Robert Hannah, Hazel Joan Dyke, Robert John Watson, John Fraser Keily, Andrew Douglas Baxter
-
Patent number: 6506774Abstract: The use of orexin receptor antagonists as neuroprotectants, and in the treatment of nausea and vomiting, irritable bowel syndrome and other conditions associated with visceral pain.Type: GrantFiled: November 30, 2001Date of Patent: January 14, 2003Assignee: SmithKline Beecham p.l.c.Inventors: Elaine Alison Irving, Gareth John Sanger
-
Patent number: 6506775Abstract: The invention provides a compound of formula (I): and its pharmaceutically acceptable salts, wherein R is halo C2-C8 alkenyl or halo C2-C8 alkynyl; R1 is hydrogen, halo or C1-C6 alkoxy; or R and R1, together with the two carbon atoms to which they are attached, form a C4-C6 cycloalkyl or a C4-C6 oxacycloalkyl ring wherein said ring may be optionally substituted by one or more substituents selected from the group consisting of halo, C1-C6 alkyl and halo C1-C6 alkyl; X is C1-C6 alkoxy, halo C1-C6 alkoxy, phenoxy or halo; and Ar is phenyl optionally substituted by halo. These compounds are useful in the treatment of a gastrointestinal disorder; a central nervous system (CNS) disorder; an inflammatory disease; emesis; urinary incontinence; pain; migraine; sunburn; diseases, disorders and adverse conditions caused by Heliobacter pylori; or angiogenesis especially CNS disorders in a mammalian subject, especially humans.Type: GrantFiled: May 1, 2000Date of Patent: January 14, 2003Assignee: Pfizer INCInventors: Kunio Satake, Yuji Shishido, Hiroaki Wakabayashi
-
Patent number: 6506777Abstract: The present invention is directed to compounds of the formula I: (wherein R1, R2, R3, R4, R5, R7, R8, X, n, x and y are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.Type: GrantFiled: June 8, 2000Date of Patent: January 14, 2003Assignee: Merck & Co., Inc.Inventors: Paul E. Finke, Jennifer L. Loebach, Malcolm Maccoss, Sander G. Mills
-
Patent number: 6506778Abstract: The invention is directed to acylphenylurea derivatives and their physiologically tolerated salts and physiologically functional derivatives. Compounds of the formula I in which the radicals have the stated meanings, and their physiologically tolerated salts and a process for their preparation are described. The compounds are suitable, for example, for treating type II diabetes.Type: GrantFiled: June 8, 2001Date of Patent: January 14, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Elisabeth Defossa, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Karl-Heinz Baringhaus
-
Patent number: 6506779Abstract: The present invention relates to compounds of the formula wherein R1, R2, R3, R4, R5, R6, X and Y are defined as in the specification, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the invention are useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock.Type: GrantFiled: November 28, 2000Date of Patent: January 14, 2003Assignee: Pfizer Inc.Inventors: Hengmiao Cheng, Akiyoshi Kawai
-
Patent number: 6506780Abstract: This invention relates to a series of substituted benzophenone and sulfone compounds of the formula I wherein ring A, Z, Y, R and X are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.Type: GrantFiled: July 2, 2001Date of Patent: January 14, 2003Assignee: Pfizer Inc.Inventor: John A. Lowe, III
-
Patent number: 6506781Abstract: A method is disclosed for rational design of a PPAR, FXR, LXR-alpha, or LXR-beta antagonist comprising chemical modification of a PPAR, FXR, LXR-alpha, or LXR-beta agonist to: a) prevent formation of a hydrogen bond between the agonist and tyrosine or histidine, or tryptophan involved in receptor activation; and/or b) displace the tyrosine or histidine, or tryptophan involved in receptor activation from its agonist bound position. Preferably, little or no additional changes are made in the structure of the agonist so that the resulting antagonist is a close structural analogue of the agonist.Type: GrantFiled: March 7, 2002Date of Patent: January 14, 2003Assignee: SmithKline Beecham CorporationInventors: Jeffrey Edmond Cobb, Millard Hurst Lambert, III, Michael Vance Milburn, Barry George Shearer
-
Patent number: 6506782Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.Type: GrantFiled: February 27, 1998Date of Patent: January 14, 2003Assignees: Athena Neurosciences, Inc., Eli Lilly CompanyInventors: Eugene D. Thorsett, Warren J. Porter, Jeffrey S. Nissen, Lee H. Latimer, James E. Audia, James Droste
-
Patent number: 6506783Abstract: A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals and can be used to treat viral infections that comprises a fungicide is disclosed. The particular fungicide used is a benzimidazole derivative having the formula: wherein R is selected from the group consisting of H, carboxyl (—CO2H), hydroxyl, amino or esters (—CO2R′) wherein R′ is selected from the group consisting of alkoxy, haloalkyl, alkenyl, and cycloalkyl wherein the alkyl groups have from 1-8 carbons or CH3CH2(OCH2CH2)n—or CH3CH2CH2(OCH2CH2CH2)n—or (CH3)2CH—(OCH(CH3)CH2)n—wherein n is from 1-3, the pharmaceutically acceptable salts thereof, or mixtures thereof.Type: GrantFiled: May 16, 1997Date of Patent: January 14, 2003Assignee: The Procter & Gamble CompanyInventor: James Berger Camden
-
Patent number: 6506784Abstract: The present invention is directed to inhibiting pest GABA receptors by contacting said receptors with a compound of Formula I: The invention is also directed to methods of controlling pests, especially insects and arachnids such as fleas and ticks, and to novel compounds within the scope of Formula I.Type: GrantFiled: June 29, 2000Date of Patent: January 14, 2003Assignees: 3-Dimensional Pharmaceuticals, Inc., Heska CorporationInventors: Daljit S. Dhanoa, Dario Doller, Sanath Meegalla, Richard M. Soll, Dimitris Agrafiotis, Nancy Wisnewski, Gary M. Silver, Dan T. Stinchcomb, R. Lee Seward
-
Patent number: 6506785Abstract: Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in the affected joint of a mammal is accomplished by administering a chondroprotective compound of Formula (I): where A is hydroxy, (C1-C4)alkoxy, amino, hydroxy-amino, mono-(C1-C2)alkylamino, di-(C1-C2)alkylamino; X and Y are independently H or (C1-C2)alkyl; and n is 1 or 2; R6 is halogen, (C1-C3)alkyl, trifluoromethyl, or nitro; R9 is H; (C1-C2)alkyl; phenyl or phenyl-(C1-C2)alkyl, where phenyl is optionally mono-substituted by fluoro or chloro; —C(═O)—R, where R is (C1-C2)alkyl or phenyl, optionally mono-substituted by fluoro or chloro; or —C(═O)—O—R′, where R1 is (C1-C2)alkyl. This treatment ameliorates, diminishes, actively treats, reverses or prevents any injury, damage or loss of articular cartilage or subchondral bone subsequent to said early stage of said degeneration.Type: GrantFiled: April 1, 1999Date of Patent: January 14, 2003Assignee: Pfizer, Inc.Inventors: Nigel A. Evans, Carolyn R. Kilroy, Kristin M. Lundy, Jean-Pierre Pelletier, Anthony P. Ricketts
-
Patent number: 6506786Abstract: A compound selected from the group consisting of a compound of formula I a compound of formula II and when the compound of formula I and II comprises an amino group pharmaceutically acceptable ammonium salts thereof, wherein R1, R2, Cx, n, R3, R4, R5, Y are as defined in the specification.Type: GrantFiled: February 13, 2001Date of Patent: January 14, 2003Assignee: Pharmacor Inc.Inventors: Brent Richard Stranix, Gilles Sauvé, Abderrahim Bouzide, Alexandre Coté, Gervais Bérubé, Patrick Soucy, Yongsen Zhao, Jocelyn Yelle
-
Patent number: 6506787Abstract: A compound of the formula: wherein R1 is hydrogen, lower alkyl, or optionally substituted arylsulfonyl, or the like, R2 is hydrogen, lower alkyl, or optionally substituted aralkyl, or the like, R3, R4, R5, and R6 each is independently hydrogen, halogen, trihalogenated lower alkyl, or the like, X is hydroxy or optionally substituted amino, Y is COOR (R is hydrogen or an ester residue), optionally substituted aryl, or optionally substituted heteroaryl, has integrase inhibition activity, and is useful as an anti-HIV drug.Type: GrantFiled: August 15, 2001Date of Patent: January 14, 2003Assignee: Shionogi & Co., Ltd.Inventors: Toshio Fujishita, Tomokazu Yoshinaga
-
Patent number: 6506788Abstract: The present invention relates to pharmaceutical compositions comprising and methods of using an N-linked urea or carbamate of a heterocyclic thioester for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance.Type: GrantFiled: August 14, 1998Date of Patent: January 14, 2003Assignee: GPI Nil Holdings, Inc.Inventors: Douglas T. Ross, Hansjörg Sauer, Gregory S. Hamilton, Joseph P. Steiner
-
Patent number: 6506789Abstract: A PGD2 receptor antagonist such as a compound of the formula (IA-a-5): a pharmaceutical acceptable salt thereof or a hydrate thereof, has an efficacious activity for the prevention or treatment of itching and is useful as a medicament.Type: GrantFiled: June 18, 2001Date of Patent: January 14, 2003Assignee: Shionogi & Co., Ltd.Inventor: Akinori Arimura
-
Patent number: 6506790Abstract: This invention relates to substituted benzo[1,2-b:5,4-b′]dipyran-4-amines which are modulators, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and a topic disorders (for example, a topic dermatitis and allergies), rheumatoid arthritis, sarcoidosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease, all in mammals, by the use of substituted benzo[1,2-b:5,4-b′]dipyran-4-amines which are CCR5 receptor antagonists. Furthermore, since CD8+T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therpeutic in the treatment of COPD. Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.Type: GrantFiled: August 29, 2001Date of Patent: January 14, 2003Assignee: SmithKline Beecham CorporationInventors: Frank E. Blaney, William E Bondinell, James A. Chan
-
Patent number: 6506791Abstract: A method of treating protozoan infections in fish comprising introducing a sufficient quantity of one or more photoactive dyes to an aqueous environment containing one or more fish infected with protozoa such that the resulting concentration of the one or more photoactive dyes in the aqueous environment is toxic to at least some of the protozoa.Type: GrantFiled: August 3, 2001Date of Patent: January 14, 2003Assignee: Jacksonville State UniversityInventor: Benjamin G. Blair
-
Patent number: 6506792Abstract: The instant invention relates to sulphamate compounds of formula I, wherein A represents a ring structure, B represents a ring structure, D a ring structure, C is a bond, E is a link joining ring structure B to the ring structure D, X represents a suitable first group, and Y represents a suitable second group; wherein one ring of the compound is a phenolic ring; and wherein any one of ring structures A, B and D has a bound thereto a sulphamate group.Type: GrantFiled: August 14, 2000Date of Patent: January 14, 2003Assignee: Sterix LimitedInventors: Michael John Reed, Barry Victor Lloyd Potter
-
Patent number: 6506793Abstract: The present invention provides a citral acetal capable of sustaining a lemon aroma unique to citral and a perfume composition comprising the citral acetal, as well as an LDH inhibitor and a deodorant, cosmetics and a skin agent for external application, comprising the LDH inhibitor. The citral acetal of the present invention is represented by formula (1): wherein the wavy line represents a cis and/or trans form, and R represents a C1, to C9, linear or branched alkyl group.Type: GrantFiled: October 10, 2001Date of Patent: January 14, 2003Assignee: Kao CorporationInventors: Sakuya Tanaka, Shigeyoshi Tanaka, Shunichi Akiba, Katsutoshi Ara, Hirohiko Ishida
-
Patent number: 6506794Abstract: An aqueous dispersion comprising a halopropargyl compound (HPC) and a partially hydrolysed polyvinyl alcohol (PHPVA). The aqueous dispersions are useful for inhibiting the growth of micro-organisms on or in a medium, especially an industrial medium such as paint films, metal working fluids, wood, latices and plastic materials.Type: GrantFiled: September 26, 2001Date of Patent: January 14, 2003Assignee: Avecia Inc.Inventors: Emerentiana Sianawati, John Edward Yates
-
Patent number: 6506795Abstract: A chromium-free wood preservative consisting essentially of 1 to 35% by weight of a mixture of 25 to 75 parts by weight of a fatty amine ethoxylate and 75 to 25 parts by weight of at least one member of the group consisting of an unsaturated fatty acid of 3 to 25 carbon atoms and their copper and zinc salts and water.Type: GrantFiled: March 26, 1996Date of Patent: January 14, 2003Assignee: WEYL GmbHInventors: Volker Barth, Helmut Hartner, Volker Beez
-
Patent number: 6506796Abstract: Methods of cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of 6-3-(1-adamantyl)-4-hydroxyphenyl)-2-naphthanoic acid.Type: GrantFiled: July 25, 2000Date of Patent: January 14, 2003Assignee: Centre International de Recherches Dermatologiques GaldermaInventors: Laszlo Fesus, Zsuzsa Szondy, Uwe Reichert
-
Patent number: 6506797Abstract: The invention provides novel substituted phenylpropanoic acid derivatives that activate by binding to receptor as ligands of human peroxisome preliferant-activated receptor &agr; (PPAR&agr;), and exhibit potent decreasing action on lipids in blood (cholesterol and triglyceride). It relates to a substituted phenylpropanoic acid derivatives represented by a general formula (1), their pharmaceutically acceptable salts and their hydrates, and processes for preparing them.Type: GrantFiled: December 10, 2001Date of Patent: January 14, 2003Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Masahiro Nomura, Yukie Takahashi, Takahiro Tanase, Hiroyuki Miyachi, Masaki Tsunoda, Tomohiro Ide, Koji Murakami
-
Patent number: 6506798Abstract: The invention provides compounds of formula (II), wherein Ar, R3, R4, R5, R6, R7, R8 and W have the meanings given in the description. They are selective MEK inhibitors.Type: GrantFiled: July 11, 2001Date of Patent: January 14, 2003Assignee: Warner-Lambert CompanyInventors: Stephen Barrett, Haile Tecle
-
Patent number: 6506799Abstract: The present invention relates to methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension comprising administering a composition comprising an ether compound.Type: GrantFiled: March 31, 2000Date of Patent: January 14, 2003Assignee: Esperion Therapeutics, Inc.Inventor: Jean-Louis Henri Dasseux
-
Patent number: 6506800Abstract: Pesticidal 1,4-diaryl-2,3-difluoro-2-butene compounds of formula I wherein Ar is phenyl, 1- or 2-naphthyl or a 5- or 6-membered heteroaromatic ring all of which aromatic systems may be optionally substituted; R is C2-C6-alkenyl, C4-C6-cycloalkenyl or C1-C2-alkoxy-C2-C6-alkyl; and Ar1 is phenoxyphenyl, phenyl, biphenyl, phenoxypyridyl, benzylpyridyl, benzylphenyl, benzoylphenyl, 1- or 2-naphthyl, or a 5- or 6-membered heteroaromatic ring all of which aromatic systems may be optionally substituted, intermediates and methods for the preparation of compounds of formula I and compositions and methods comprising the compounds and compositions for the control of insect and acarid pests.Type: GrantFiled: September 12, 2001Date of Patent: January 14, 2003Assignee: BASF AktiengesellschaftInventor: Terence James Bentley
-
Patent number: 6506801Abstract: The present invention provides methods of treating complicated anosmia in a mammal, methods of enhancing the rate of olfactory nerve recovery in a mammal, and methods of enhancing nerve regeneration in a mammal by administering an effective amount of a retinoid compound to the mammal.Type: GrantFiled: October 2, 2001Date of Patent: January 14, 2003Assignee: Monell Chemical Senses CenterInventors: Karen K. Yee, Nancy E. Rawson
-
Patent number: 6506802Abstract: Novel disulfide derivatives useful for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The disulfide derivatives act as mast cell stabilizers.Type: GrantFiled: May 22, 2002Date of Patent: January 14, 2003Assignee: Alcon Universal Ltd.Inventors: Zixia Feng, Mark R. Hellberg, Steven T. Miller
-
Patent number: 6506803Abstract: The present invention provides methods and compositions for inactivating bacteria including bacterial spores using an oil-in-water emulsion are provided. The oil-in-water emulsion comprises an oil, a surfactant and an organic phosphate-based solvent. These methods can be used to inactivate a wide variety of microorganisms including bacteria, bacterial spores, fungi, fungal spores and enveloped viruses.Type: GrantFiled: April 28, 2000Date of Patent: January 14, 2003Assignee: Regents of the University of MichiganInventors: James R. Baker, Jr., Tarek Hamouda, Amy Shih, Andrzej Myc
-
Patent number: 6506804Abstract: Disclosed are ethylenically unsaturated amine salts of sulfonic, phosphoric and carboxylic acids. The salts are surface active agents which are useful in a variety of applications as primary and/or secondary surfactants. The salts are especially useful as surfactants in emulsion polymerization reactions.Type: GrantFiled: March 8, 2001Date of Patent: January 14, 2003Assignee: Stepan CompanyInventor: Alfred K. Schultz
-
Patent number: 6506805Abstract: A magnesium ammonium phosphate slurry and method of producing magnesium ammonium phosphate slurries. The method provides for obtaining a magnesium hydroxide supply having a small particle size of about 2 microns. Aqua ammonia and phosphoric acid are sequentially added while maintaining the temperature at below 110° F. The magnesium ammonium phosphate hexahydrate slurry formed has a small particle size of about 2 to 7 microns. The hexahydrate slurry may be converted to a monohydrate slurry having a particle size of less than about 8 microns by heating to the boiling point in the presence of excess water or heating to the boiling point while maintaining a very moderate hydrostatic pressure.Type: GrantFiled: August 17, 2001Date of Patent: January 14, 2003Inventors: J. Richard Green, Warren D. Winterson
-
Patent number: 6506806Abstract: A composition for reducing surface tension comprising from about 0.1% to about 0.5% by weight of a hydrocarbon surfactant and from 0.0001% to about 0.3% by weight of a fluorocarbon surfactant, provided that the hydrocarbon surfactant is present at less than or equal to 0.08% by weight when the fluorocarbon surfactant is present at greater than or equal to 0.Type: GrantFiled: May 15, 2001Date of Patent: January 14, 2003Assignee: E. I. du Pont de Nemours and CompanyInventors: Charles Kenneth Taylor, Kai Volker Schubert, Richard David Koehler
-
Patent number: 6506807Abstract: A process for preparing pre-expanded particles of a thermoplastic resin without washing the prepared pre-expanded particles to remove a dispersing agent remaining thereon and without discharging waste water, which comprises charging particles of a thermoplastic resin and an aqueous dispersion medium containing a dispersing agent into a closed pressure vessel, heating the resulting aqueous dispersion to a temperature of not less than the softening point of the thermoplastic resin, thereby impregnating the particles with water to have a water content of 1 to 50% by weight, releasing the dispersion into a lower pressure atmosphere, thereby expanding the particles, recovering the dispersion medium containing the dispersing agent, and recycling it as a dispersion medium to the pressure vessel.Type: GrantFiled: June 13, 2000Date of Patent: January 14, 2003Assignee: Kaneka CorporationInventors: Yutaka Yanagihara, Kenji Mogami, Naruhiko Akamatsu
-
Patent number: 6506808Abstract: Microcellular rigid foams with a matrix consisting of cross-linked duromers, especially of polytriazine resins, and with an apparent density of 20 to 95 percent of the density of the compact matrix material. The rigid foams are highly stable and highly temperature resistant and are suitable for use, e.g., as material for aircraft lining.Type: GrantFiled: July 10, 2000Date of Patent: January 14, 2003Assignee: Lonza AGInventors: Ulrich Daum, Dietmar Rakutt
-
Patent number: 6506809Abstract: The invention concerns nucleating agent systems for foamable polymer compositions, preferably fluoropolymer resins, having foam cell nucleation sites using titanium dioxide based nucleating agents, and foamable polymers comprising the nucleating agents. The nucleating agent systems comprise TiO2, certain inorganic salts, and, optionally, sulfonic acid salts and/or phosphonic acid salts. The invention also concerns foamable composition concentrates and foamed thermoplastic insulation material comprising fluoropolymer and the nucleating agent systems.Type: GrantFiled: April 17, 2002Date of Patent: January 14, 2003Assignee: Ausimont USA, Inc.Inventor: Jeffrey A. Hrivnak
-
Patent number: 6506810Abstract: The invention relates to the use of mixtures of organofunctionally modified polysiloxanes with branched alcohols in the production of flexible polyurethane foams.Type: GrantFiled: November 26, 2001Date of Patent: January 14, 2003Assignee: Goldschmidt AGInventors: Rob Borgogelli, Oliver Eyrisch
-
Patent number: 6506811Abstract: Carbamate solutions are obtainable by reacting at least one alkanolamine with carbon dioxide in, as solvent, at least one organic compound having a molecular weight of from 60 to 600 and containing at least one hydroxyl group, wherein the carbamate contains at least 0.Type: GrantFiled: September 28, 2001Date of Patent: January 14, 2003Assignee: BASF AktiengesellschaftInventors: Peter Woo, Anke Schulze, Edmund Stadler, Dieter Tintelnot, Udo Hadick, Ralf Hinrichs, Horst Hürkamp, Klaus Sobolewski
-
Patent number: 6506812Abstract: A thermosetting plastic foam solid formed from the reaction product of: (a) either polyisocyanate or isocyanate-based foam; (b) a polyol-based foam; (c) a catalyst which is capable of promoting the thermosetting reaction between the polyisocyanate or isocyanate-based foam and the polyol-based foam; and (d) a blowing agent which comprises a high purity cyclopentane product, wherein the high purity cyclopentane product is about 95% or greater pure cyclopentane, and, optionally, (e) water and/or (f) liquid flame retardant.Type: GrantFiled: July 24, 2001Date of Patent: January 14, 2003Assignee: Exxon Mobil Chemical Patents IncInventors: Robert H. Blanpied, James Darryl Thornsberry, Steven E. Silverberg, James R. Lattner, C. Harry McMullen, Leonel E. Sanchez, Tronze-I Dennis Wu
-
Patent number: 6506813Abstract: The invention relates to a polyol composition comprising b1) a polyol where the EO content is at least 50%; b2) a polyol having a primary hydroxyl content of at least 50%; b3) an amine-initiated polyoxypropylene polyol having an OH value greater than 400, according to the following proportions: b1: 20-70 wt %, b2: 5-50 wt %, b3: 5-50 wt %. The invention also relates to a process for preparing a cold-setting flexible polyurethane foam at NCO index of 70-120 by reacting a) a polyisocyanate; the polyols b1), b2) and b3); c) water; and d) additives and auxiliaries known per se. The invention finally relates to a reaction system comprising A) a polyisocyanate and B) an isocyanate-reactive component comprising the polyols b1), b2) and b3).Type: GrantFiled: January 10, 2002Date of Patent: January 14, 2003Assignee: Huntsman International, LLCInventors: Alain Parfondry, Jianming Yu
-
Patent number: 6506814Abstract: A UV-curable acrylate-thiol-ene insulating coating composition for electrical conductors, a method of manufacturing a UV-curable acrylate-thiol-ene insulating coating composition for electrical conductors. The insulating coating being of about 2.5 &mgr;m to about 500 &mgr;m thickness, which cured coating has a dielectric dissipation factor (60 Hz, 24° C.) of lower than about 0.05.Type: GrantFiled: May 7, 1998Date of Patent: January 14, 2003Assignee: DSM N.V.Inventors: Vadim V. Krongauz, Chau T. M. Ha, Sangeeta Rampuria
-
Patent number: 6506815Abstract: A resin composition for denture is provided, which does not require operations for weighing, and mixing during the use; is free from involving of air bubbles; and when used for preparation of a denture base, is free from a reduction in physical properties and staining or discoloration with a lapse of time. Further, a completed denture has a high elastic energy value, is superior in impact resistance, and when applied with an impact or a stress as in the case of dropping, is not readily broken. The resin composition for denture base is in a one-paste state and is constructed by (a) a polymerizable monomer and/or oligomer having a modulus of elasticity at polymerization of 0.25 to 3.00 GPa, (b) an organic filler and/or an organic-inorganic composite filler having a modulus of elasticity of 0.25 to 3.00 GPa, and (c) a polymerization initiator made of a heat polymerization type polymerization initiator and/or a photopolymerization type polymerization initiator, and optionally, (d) an inorganic filler.Type: GrantFiled: September 10, 2001Date of Patent: January 14, 2003Assignee: GC CorporationInventors: Yutaka Shinozaki, Tomohiro Kumagai